Agenda
IDEOlogy Health’s 2026 Texas Gastrointestinal Cancer Conference will bring together multidisciplinary experts to explore the latest advances in gastrointestinal cancer care, with a focus on translating innovation into practical strategies for community oncology. The agenda will feature CE and non-CE sessions, including symposia, panel discussions, and keynote presentations, all designed to foster collaboration across medical, surgical, and radiation oncology.
Agenda Sessions
- The session on early-stage upper GI cancers will cover adjuvant and neoadjuvant strategies, non-operative management, and treatment of oligometastatic disease through a multidisciplinary lens.
- The late-stage upper GI session will emphasize biomarker-driven therapies—including HER2, PD-L1, CLDN18.2, and FGFR2—alongside second-line options and the integration of clinical next-generation sequencing (NGS).
- Early-stage colorectal cancer will be addressed through surgical and radiation approaches, as well as emerging immunotherapy strategies.
- The late-stage colorectal session will focus on targeted therapies for BRAF, HER2, and KRAS mutations, novel chemotherapy regimens, and liver-directed and locoregional therapies.
- A dedicated hepatobiliary session will examine systemic and multidisciplinary approaches to hepatocellular carcinoma (HCC) and biliary tract cancers (BTC).
- The “Tools for Tomorrow’s Oncologist” session will spotlight ctDNA-based minimal residual disease (MRD) testing, artificial intelligence (AI), EMR-based decision support, precision medicine, and the expanding role of advanced practice providers.
- Rare tumor types will be explored through updates on small bowel malignancies, gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NETs), and radiopharmaceutical therapies, including five new agents in development.
- A session on genetic insights will focus on cancer prevention and early detection, including germline testing and surveillance strategies.
- The pancreatic cancer session will address targeted therapies such as PARP inhibitors for BRCA mutations, perioperative regimens, and local treatments like stereotactic body radiotherapy (SBRT) and tumor treating fields (TTF).
- The “GI Evolving Landscape” session will explore pan-tumor approvals (e.g., MSI-H, NTRK fusions), antibody–drug conjugates (ADCs), and emerging clinical trials.
TXGI’26 will deliver a comprehensive, forward-looking program that equips oncology professionals with actionable insights. By bridging academic innovation with community practice, the conference will reinforce the value of multidisciplinary care in improving outcomes for patients with GI malignancies.